Links to documents associated with the Strategic Review and offer for Vernalis plc by Ligand Holdings UK Ltd.

06/SEP/2018 - Announcement - Publication and Posting of Scheme Document

06/SEP/2018 - Scheme Document

06/SEP/2018 - Forms of Proxy (Specimen)

06/SEP/2018 - Consent Letter - Canaccord

06/SEP/2018 - Consent Letter - Evercore

06/SEP/2018 - Consent Letter - finnCap

06/SEP/2018 - Ligand UK Articles of Association

06/SEP/2018 - Vernalis plc Articles of Association - CURRENT

06/SEP/2018 - Vernalis plc Articles of Association - AMENDED

06/SEP/2018 - Rule 15 Value Builder Plan Optionholder Letter

06/SEP/2018 - Rule 15 Long Term Incentive Plan Optionholder Letter

 

16/AUG/2018 - Board Change

09/AUG/2018 - Rule 2.7 Announcement - Recommended Cash Offer for Vernalis plc

09/AUG/2018 - Rule 2.11 Letter to Shareholders of Vernalis plc

09/AUG/2018 - Break Free Letter

09/AUG/2018 - Canaccord Genuity Consent Letter

09/AUG/2018 - Confidentiality Agreement

09/AUG/2018 - Co-operation Agreement

09/AUG/2018 - Evercore Consent Letter

09/AUG/2018 - Finncapp Consent Letter

09/AUG/2018 - Form of Director Irrevocable Undertaking - Carol Ferguson

09/AUG/2018 - Form of Director Irrevocable Undertaking - David Mackney

09/AUG/2018 - Form of Director Irrevocable Undertaking - Ian Garland

09/AUG/2018 - Form of Director Irrevocable Undertaking - Nigel Sheail

09/AUG/2018 - Form of Director Irrevocable Undertaking - Peter Fellner

09/AUG/2018 - Irrevocable Undertaking - Invesco Asset Management Limited

09/AUG/2018 - Irrevocable Undertaking - Woodford Investment Management Limited

15/JUN/2018 - Rule 2.9 Announcement

14/JUN/2018 - Termination of Tris Agreement and Update on Formal Sale Process

18/MAY/2018 - Rule 2.9 Announcement

29/MAR/2018 - Public Opening Position Disclosure by a Party to an Offer 

28/MAR/2018 - Unaudited Interim Results for the six months ended 31 December 2017

21/MAR/2018 - Rule 2.9 Announcement

19/MAR/2018 - Option holder Letter

19/MAR/2018 - Shareholder Letter

15/MAR/2018 - Vernalis plc Update on Strategic Review, Formal Sale Process and Forthcoming Directorate Changes - Press Release

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch